Leerink Partnrs Estimates Editas Medicine FY2025 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($1.06) for the year, down from their previous forecast of ($1.05). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for Editas Medicine’s FY2026 earnings at ($0.65) EPS.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.75) EPS for the quarter, hitting the consensus estimate of ($0.75). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The company had revenue of $0.06 million during the quarter, compared to the consensus estimate of $3.93 million. During the same quarter last year, the firm posted ($0.55) EPS. The company’s quarterly revenue was down 98.9% on a year-over-year basis.

EDIT has been the subject of several other reports. Truist Financial downgraded Editas Medicine from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. JPMorgan Chase & Co. downgraded Editas Medicine from a “neutral” rating to an “underweight” rating in a report on Monday, December 16th. Stifel Nicolaus lowered shares of Editas Medicine from a “buy” rating to a “hold” rating and decreased their price target for the company from $11.00 to $3.00 in a research note on Friday, December 13th. Evercore ISI dropped their price objective on shares of Editas Medicine from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday, December 16th. Finally, Robert W. Baird decreased their target price on shares of Editas Medicine from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.00.

Editas Medicine Stock Performance

NASDAQ:EDIT opened at $1.41 on Friday. The firm has a fifty day simple moving average of $1.70 and a two-hundred day simple moving average of $3.15. Editas Medicine has a 12 month low of $1.12 and a 12 month high of $11.58.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of EDIT. Signaturefd LLC raised its stake in shares of Editas Medicine by 494.8% during the 3rd quarter. Signaturefd LLC now owns 9,326 shares of the company’s stock worth $32,000 after purchasing an additional 7,758 shares during the period. Ballentine Partners LLC bought a new stake in shares of Editas Medicine in the 3rd quarter worth approximately $36,000. Thrive Wealth Management LLC bought a new position in Editas Medicine during the fourth quarter valued at $36,000. Arcadia Investment Management Corp MI purchased a new stake in Editas Medicine in the third quarter worth $39,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Editas Medicine in the third quarter valued at $47,000. Hedge funds and other institutional investors own 71.90% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.